

The Usefulness of Saliva as a Biological Material for the Determination of Pharmacokinetics of Model Drugs (Antipyrine, Caffeine, Paracetamol) in Calves: Comparative Study

¹Zbigniew Muszczynski, ¹Krzysztof Janus, ²Ewa Skotnicka,
¹Karol Fijalkowski and ¹Dorota Jankowiak

¹Department of Immunology, Microbiology and Physiological Chemistry,
Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology,
Szczecin, Doktora Judyma 26, 71-466 Szczecin, Poland

²Department of Physiology, Faculty of Natural Science,
University of Szczecin, Felczaka 3C st, 71-412 Szczecin, Poland

Abstract: The aim of this study was to evaluate usefulness of saliva as a biological material for determination of pharmacokinetics of model drugs (antipyrine, caffeine and paracetamol) in calves at different age. For the experiment, 30 Black and White calves (BW) at the age of 10 and 40 days were divided into three groups. The calves of group I received antipyrine (10 mg kg⁻¹ bw.), group II caffeine (5 mg kg⁻¹ bw.) and group III paracetamol (10 mg kg⁻¹ bw.). Samples of blood and saliva were collected from all examined animals. The concentration of antipyrine and paracetamol was measured spectrophotometrically. The concentration of caffeine was evaluated by EMIT method. The pharmacokinetics of antipyrine were estimated using one-compartment model whereas the pharmacokinetics of caffeine and paracetamol using non-compartment model. The following pharmacokinetic parameters were evaluated: volume of distribution, relative volume of distribution, mean residence time; biological half-life, metabolic clearance, relative metabolic clearance and level of model drugs-plasma proteins fractions. Results obtained in the experiment (not statistically significant differences in pharmacokinetic parameter values of antipyrine and caffeine and statistically significant according to paracetamol) determined on the basis of model drugs concentration in blood and saliva showed that saliva has potential to be used as a biological material from calves but only for evaluation of pharmacokinetics of antipyrine and caffeine. However, it cannot be used for assessment of pharmacokinetics of paracetamol.

Key words: Antipyrine, caffeine, paracetamol, pharmacokinetic, plasma, saliva, calves

INTRODUCTION

Activity of enzymes which catalyse biotransformation of xenobiotics can be evaluated under *in vivo* and *in vitro* conditions. Recently an increasing recognition of *in vivo* methods which involve implementation of model drugs is observed (Boothe *et al.*, 1994; De Graves *et al.*, 1995; Danielson and Golsteyn, 1996; Engelking *et al.*, 1987; Higaki *et al.*, 2003; Janus and Grochowina, 2006b).

Antipyrine is a model drug which is used for determination of rate of the first phase of hepatic bio-transformation (mostly oxidation); those reactions are catalysed by microsomal monooxygenases which form complex with cytochrome P450 (CYP450); an enzymatic complex which is crucial in oxidative

metabolism of xenobiotics (Monshouwer *et al.*, 1994; Delpchin *et al.*, 1988; Janus and Suszycka, 1996). Major metabolites of antipyrine are: 4-hydroxyandro-stenedione (4-OHA), 3-Hydroxymethylantipyrine (HMA) and Norantipyrine (NORA) (Monshouwer *et al.*, 1994; Delpchin *et al.*, 1988; Welch *et al.*, 1975).

Caffeine (1, 3, 7-trimethylxanthine) is very common pharmacological product which stimulates e.g., central nervous system and circulatory system (Zylber-Katz *et al.*, 1984; Monshouwer *et al.*, 1995; Peck *et al.*, 1997). Isoenzymes involved in the caffeine metabolism belong to cytochrome P450 complex (mainly CYP1A2 isoform). Major metabolites which are produced as a result of caffeine demethylation in 1, 3 and 7 position are theobromine, paraxanthine and theophylline (Boothe *et al.*, 1994; Zylber-Katz *et al.*, 1984;

Corresponding Author: Zbigniew Muszczynski, Department of Immunology, Microbiology and Physiological Chemistry, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, Dr Judyma 24, 71-466 Szczecin, Poland

De Graves *et al.*, 1995; Danielson and Golsteyn, 1996). Caffeine is transformed by N-acetyltransferase (NAT) and xanthine oxidase (De Graves *et al.*, 1995; Danielson and Golsteyn, 1996; Aramaki *et al.*, 1991). This model drug is nearly completely transformed in the liver. Only 2-5% of caffeine after administration into the organism is excreted (in unchanged form) in urine (Boothe *et al.*, 1994; Danielson and Golsteyn, 1996).

Paracetamol is derivative of aniline (Engelking *et al.*, 1987; Adzu *et al.*, 2001; Bannwarth and Pehourcq, 2003). Except its therapeutic use, it is also a tool in pharmacokinetic research as a model substance for examination factors effecting activity of enzymes involved in processes of second phase of hepatic biotransformation (Higaki *et al.*, 2003; Janus *et al.*, 2003; Li *et al.*, 2004; Janus and Grochowina 2006a, b).

Bonding of paracetamol with plasma proteins does not inhibit the rate of its elimination due to dissociation of the drug-protein complex (Mansor *et al.*, 1991; Bannwarth and Pehourcq, 2003; Li *et al.*, 2004). Paracetamol is completely metabolized in the liver (McNamara *et al.*, 1991; Allegaert *et al.*, 2004b; Bannwarth and Pehourcq, 2003; Li *et al.*, 2004). It undergoes coupling reactions mostly with glucuronic acid by glucuronic transferase (Ali *et al.*, 1996; Bock *et al.*, 1987; Higaki *et al.*, 2003; Janus *et al.*, 2003) and with sulphite ions by phenylsulfotransferase (Wynne *et al.*, 1990; Higaki *et al.*, 2003; Janus *et al.*, 2003).

Only 3-4% of paracetamol is oxidised into transitional form of N-acetylobenzochinoimine. The reaction is catalyzed by cytochrome P450 (Flouvat *et al.*, 2004; Li *et al.*, 2004). In humans adults humans, products of oxidative metabolism of paracetamol are <10% of all its metabolites however, in newborns reach 10-20% (Allegaert *et al.*, 2004a, b).

Now a days, saliva is increasingly used as biological material to determine pharmacokinetics of model drugs in humans (Zylber-Katz *et al.*, 1984; Posti, 1999; Linday *et al.*, 1991; Babalola *et al.*, 2004) and animals Lakin *et al.*, 1997; Meffin *et al.*, 1977; Janus *et al.*, 2003; Kennedy *et al.*, 2003). However, until now the possibility of using saliva for determination of the range of pharmacokinetic parameters of drugs which would allow for evaluation of both phases of hepatic biotransformation was not investigated.

The aim of this study was to evaluate usefulness of saliva as a biological material for determination of pharmacokinetics of model drugs in calves at different age.

MATERIALS AND METHODS

The experimental material: For the experiment (approved by the localethic committee for scientific experiments on animals) 30 Black and White calves (BW) at the age of

10 and 40 days were divided into 3 groups: I-antipyrene group, II-caffeine group and III-paracetamol group. During the whole experiment, all animals were kept in the same standard environmental conditions. Before the experiment, external jugular vein catheterization was conducted on all animals. Any drugs which could interact pharmacokinetically and biochemically with antipyrene, caffeine and paracetamol were not administrated to animals during the experiment.

Experimental procedure

Antipyrene test: Calves of group I received intravenous antipyrene at dose of 10 mg kg⁻¹ body weight (bw). Blood and saliva samples were collected before administration of antipyrene (0) and then after 1, 2, 4, 6, 8, 12 and 24 h after the drug was given.

Caffeine test: Calves of group I received intravenous caffeine at dose of 5 mg kg⁻¹ bw. Samples of blood and saliva were collected before (0) administration of caffeine and then after 1, 2, 4, 6, 8, 12 and 24 h after the drug was given.

Paracetamol test: Calves of group III received intravenous paracetamol at dose of 10 mg kg⁻¹ bw. Samples of blood and saliva were collected before (0) administration of paracetamol and then after 0.5, 1, 1.5, 2, 3, 4, 5, 6 and 8 h after administration.

Doses of model drugs and time-points of blood sample collection were established on the basis of the previous experiments (Janus and Suszycka, 1996; Janus *et al.*, 2003, 2007).

Blood samples were aseptically collected into tubes with heparin as a coagulant and then centrifuged (4000×g for 15 min) in order to obtain plasma. Simultaneously, saliva was centrifuged in order to obtain mucopolysaccharides. All samples were aliquoted and frozen at -20°C until further use.

The concentration of antipyrene and paracetamol was measured spectrophotometrically. The concentration of caffeine was evaluated by EMIT method (Enzyme Multiplied Immunoassay Technique) (Boothe *et al.*, 1994; De Graves *et al.*, 1995).

Pharmacokinetic calculations: The pharmacokinetic of antipyrene was estimated using open one-compartment model (Engelking *et al.*, 1987). Calculations were carried out on the basis of elimination curves for that model substance. The determinations was made at free phase (β) elimination (Depelchin *et al.*, 1988; Welch *et al.*, 1975). The levels of pharmacokinetic parameters of caffeine and paracetamol were estimated using non-compartment

model (Aramaki *et al.*, 1991; Janus *et al.*, 2003). The following pharmacokinetic parameters were evaluated: volume of distribution V_d (l), relative volume of distribution V_d (kg^{-1}), mean residence time $T_{1/2\beta}$ (h); biological half-life (MRT), Metabolic clearance Cl_m (mL min^{-1}), relative metabolic clearance Cl_m (mL/min/kg) and level of model drugs-plasma proteins fractions (F_B).

Statistical analysis: All statistical analysis were conducted with Statistica 6.0 software. The statistical significance of the differences between pharmacokinetic parameters of antipyrine, caffeine and paracetamol in plasma versus saliva in calves at age of 10 and 40 days was determined by Student's t-test.

RESULTS

Results obtained in the experiment are shown in Table 1 and 2. The statistical significance of the differences between pharmacokinetic parameters of antipyrine, caffeine and paracetamol in plasma versus saliva in calves at age of 10 and 40 days are shown in Table 3.

It was reported that levels of pharmacokinetic parameters of all model drugs in calves were changing significantly in an age dependent manner, irrespectively of the type of material (blood or saliva) used for analyzes.

Volume of distribution of antipyrine, caffeine and paracetamol between 10th and 40th day of experiment increased of 35.4, 30.7; 38.6, 34.3, 40.0 and 44.4%, respectively for plasma and saliva. The different pattern was obtained for distribution coefficient which was

decreasing with age (antipyrine: -9.8 and -12.9%; caffeine: -8.9 and -10.5%; paracetamol: -20.1 and -14.5%). Mean residence time was shortening with animals age (12.5 and 12.6% antipyrine; 11.0 and 10.1% caffeine; 25.0 and 22.1% paracetamol, respectively). Similar changes were also observed for half-life parameter: ($T_{1/2\beta}$): -12.8 and -13.0%; -9.5 and -8.5%; -21.0 and -22.5%, respectively. Changes of MRT and $T_{1/2\beta}$ values effected in an increased of absolute and relative metabolic clearance of antipyrine, caffeine and paracetamol in an age-depending pattern (absolute clearance antipyrine 73.3 and 68.3%; caffeine: 61.1 and 58.9%; paracetamol: 100.3 and 95.0% and also relative clearance 13.0 and 12.4%; 8.2 and 6.8%; 14.6 and 9.9%, respectively).

Percentage differences in values of pharmacokinetic parameters calculated on the basis of antipyrine, caffeine and paracetamol concentration in blood and saliva were: (10th day) antipyrine - V_d (l)+2.8%, V_d (l kg^{-1})+2.9%, MRT +1.8%, $T_{1/2\beta}$ +1.7%, Cl_m (mL min^{-1})-5.5%, Cl_m (mL/min/kg) -4.9%; caffeine - V_d (l)+1.5%, V_d (kg^{-1})+1.5%, MRT+1.6%, $T_{1/2\beta}$ +2.6%, Cl_m (mL min^{-1})-4.5%, Cl_m (mL/min/kg) -4.6%; paracetamol - V_d (l)-11.2%, V_d (l kg^{-1})-8.0%, MRT -15.1%, $T_{1/2\beta}$ -16.9%, Cl_m (mL min^{-1}) +13.2%, Cl_m (mL/min/kg) +11.6% and at 40th day: +6.6, +6.5, +1.2, +1.9, -2.8 and -4.4% (antipyrine); +3.3, +3.3, +1.5, +1.5, -3.2 and -3.1% (caffeine); -14.1, -14.2, -18.5, -18.1, +16.3 and +16.1% (paracetamol), respectively.

Coefficient of distribution of the investigated model drugs in plasma and saliva of calves was between antipyrine 0.973-0.981; caffeine 0.965-0.975; paracetamol 0.821-0.878, respectively. The volumes of bound fraction used in the model drug experiment with plasma proteins were: 1.9-2.7% (antipyrine); 2.5-3.5% (caffeine)

Table 1: Pharmacokinetics of antipyrine, caffeine, paracetamol in plasma and saliva of 10 days old calves (x±s)

Pharmacokinetic parameters	Antipyrine		Caffeine		Paracetamol	
	Plasma	Saliva	Plasma	Saliva	Plasma	Saliva
V_d (l)	28.80±3.10	28.00±2.50	27.20±2.90	26.80±2.70	28.00±3.00	31.50±3.30
V_d (l kg^{-1})	0.72±0.06	0.70±0.08	0.68±0.05	0.67±0.07	0.70±0.06	0.76±0.09
MRT (min)	720.00±60.0	707.00±68.0	685.00±59.0	674.00±65.0	100.00±9.00	118.00±15.0
$T_{1/2\beta}$ (min)	705.00±54.0	693.00±62.0	667.00±63.0	650.00±49.0	89.00±7.00	107.00±19.0
Cl_m (mL min^{-1})	30.70±3.30	32.50±3.90	34.20±4.10	35.80±3.20	296.80±30.2	262.30±31.3
Cl_m (mL/min/kg)	0.77±0.09	0.81±0.08	0.85±0.10	0.89±0.07	7.42±0.84	6.65±0.79
FB (%)	1.90		2.50		12.20	

Table 2: Pharmacokinetics of antipyrine, caffeine, paracetamol in plasma and saliva of 40 days old calves (x±s)

Pharmacokinetic parameters	Antipyrine		Caffeine		Paracetamol	
	Plasma	Saliva	Plasma	Saliva	Plasma	Saliva
V_d (l)	39.00±4.20	36.60±2.90	37.20±3.30	36.00±3.80	39.20±3.90	45.50±4.40
V_d (l kg^{-1})	0.65±0.06	0.61±0.08	0.62±0.07	0.60±0.09	0.56±0.05	0.65±0.07
MRT (min)	630.00±55.0	619.00±51.0	615.00±63.0	606.00±69.0	75.00±7.00	92.00±10.0
$T_{1/2\beta}$ (min)	615.00±54.0	603.00±59.0	604.00±57.0	595.00±46.0	69.00±8.00	84.00±9.00
Cl_m (mL min^{-1})	53.20±4.70	54.70±5.10	55.10±49.0	56.90±5.30	595.00±60.1	511.50±49.3
Cl_m (mL/min/kg)	0.87±0.07	0.91±0.09	0.92±0.11	0.95±0.08	8.50±0.92	7.31±0.89
FB (%)	2.70		3.50		17.90	

Table 3: The statistical significance of the differences between pharmacokinetic parameters of antipyrine, caffeine and paracetamol in plasma versus saliva in calves at age of 10 and 40 days

Pharmacokinetic parameters	Antipyrine	Caffeine	Paracetamol
	-----Plasma vs. Saliva-----		
V _d (l)	p>0.05	p>0.05	p>0.05
V _d (l kg ⁻¹)	p>0.05	p>0.05	p>0.05
MRT (min)	p>0.05	p>0.05	p>0.01
T _{1/2β} (min)	p>0.05	p>0.05	p>0.01
Cl _m (mL min ⁻¹)	p>0.05	p>0.05	p>0.01
Cl _m (mL/min/kg)	p>0.05	p>0.05	p>0.01

and 12.2-17.9% (paracetamol) of the level of the present concentration of those drugs in plasma, respectively. The bound fraction values were increasing with the age of animals.

DISCUSSION

A decrease of V_d - l kg⁻¹ and an increase of V_d - l for antipyrine, caffeine and paracetamol were observed in humans and different species of animals (Hahn *et al.*, 2000; Allegaert *et al.*, 2004a, b). The results obtained in this experiment are similar to the previous findings (Janus and Suszycka, 1996; Janus and Grochowina, 2006a; Janus *et al.*, 2007) and also are consistent with other experiments performed in pigs (Monshouwer *et al.*, 1995), sheep (Danielson and Golsteyn, 1996), rabbits (McNamara *et al.*, 1991), camels (Ali *et al.*, 1996; Wasfi *et al.*, 2000), horses (Engelking *et al.*, 1987; Peck *et al.*, 1997; Aramaki *et al.*, 1991), donkeys (Peck *et al.*, 1997) and dogs (Boothe *et al.*, 1994).

Results of the experiment: Significant shortening of MRT and biological half-life used in the model drug research had the effect on the values of metabolic clearance of antipyrine, caffeine and paracetamol in calves (significantly higher values obtained in older calves 40 days old, compared to calves at neonatal stage 10 days old). Similarly to absolute and relative (l kg⁻¹) volume of distribution also changes in MRT, T_{1/2β} and Cl_m parameters are agree with previous findings from the experiments carried out in other animal species (Boothe *et al.*, 1994; Monshouwer *et al.*, 1995; Ali *et al.*, 1996; Danielson and Golsteyn, 1996; Engelking *et al.*, 1987; Peck *et al.*, 1997; McNamara *et al.*, 1991; Wasfi *et al.*, 2000; Aramaki *et al.*, 1991). Many studies proof that humans and animals' newborns have a lower metabolic efficiency of liver (Depelchin *et al.*, 1988; Janus and Suszycka, 1996; Kearns and Reed, 1989; Kawalek and El-Said, 1990; Janus and Grochowina, 2006a). It is a consequence of reduced activity of several enzymatic complexes (Kearns and Reed, 1989;

Kawalek and El-Said, 1990). However, many factors cause the increase of the ability of hepatocytes to biotransformation e.g., in the case of CYP450 complex, it is a change in proportion of cytochrome reductase and phospholipids. With age that proportion changes in favor of RED CYP450 (Kawalek and El-Said, 1990). In very young animals and newborns, it is 20/80%, however full metabolic efficiency of that complex is observed at ratio 50/50% (Kearns and Reed, 1989). Similar effect was reported also for other enzymatic systems that catalyze biotransformation of other model drugs: caffeine caused an increased in molar ratio of N-acetyltransferase to xanthine oxidase (De Graves *et al.*, 1995; Danielson and Golsteyn, 1996) and paracetamol (Engelking *et al.*, 1987; McNamara *et al.*, 1991; Janus *et al.*, 2003). Coupling of paracetamol and sulfate is a major metabolic pathway for that drug in young organisms which have not fully active glukuronylotransferse system (De Wildt *et al.*, 1999; Miners *et al.*, 1990; Janus *et al.*, 2003). Previous studies have also found that an increase in intensity of glucuronidation processes follows a decrease in intensity of sulfation and vice versa (Wynne *et al.*, 1990; Higaki *et al.*, 2003; Allegaert *et al.*, 2004a; Li *et al.*, 2004).

Predominance of one of those two main metabolic pathways (glucuronidation and sulfation) for that drug is species dependent (Monshouwer *et al.*, 1994; Ali *et al.*, 1996; De Wildt *et al.*, 1999; Adzu *et al.*, 2001; Janus *et al.*, 2003; Flouvat *et al.*, 2004). Higher activity of enzymes involved in glucuronidation compared to sulfation was reported in ruminates versus monogastric animals (Monshouwer *et al.*, 1994; Ali *et al.*, 1996). Also of not is the observation that in young organism processes of sulfation proceed about two times faster than glucuronidation (Miller *et al.*, 1976; Janus *et al.*, 2003; Li *et al.*, 2004). Non-invasiveness of sample collection is a very important advantage of using saliva as a biological material during the pharmacokinetic research (Meffin *et al.*, 1977; Posti, 1999).

Concentration of drug in saliva is a resultant of many factors (Zylber-Katz *et al.*, 1984; Lakin *et al.*, 1997). One of the major quantitative parameter of substance transportation (including model drugs) from blood to saliva is the transfer coefficient which represents the ratio of substance concentration in saliva to its concentration in plasma (Posti, 1999). The levels of that coefficient are close to value one, observed when the rate of drug transfer is higher or equal with rate of saliva secreting (Lakin *et al.*, 1997; Linday *et al.*, 1991). It was showed that majority of drugs diffuse to saliva and their ability to penetrate is correlated positively with lipophilicity and correlated negatively with particles size (Posti, 1999;

Kennedy *et al.*, 2003). It was also observed that ionized form of substance (drug) can infiltrate biological barriers at lower ratio than neutral form (Zylber-Katz *et al.*, 1984; Lakin *et al.*, 1997; Meffin *et al.*, 1977). It should be emphasized that particular attention is needed when comparing results obtained in experiments carried out in humans and different animal species an infiltration of pharmacological substances from blood to saliva is species dependent (Lakin *et al.*, 1997; Posti, 1999; Linday *et al.*, 1991; Welch *et al.*, 1975). Comparison of drug concentration values in saliva and plasma allows for determination of range of free fraction of the particular pharmacological substance (Posti, 1999; Linday *et al.*, 1991; Kennedy *et al.*, 2003).

It is known that only free fractions of drugs are able to penetrate biological membranes, bond with receptors and be transformed (Lakin *et al.*, 1997; Posti, 1999). The range of free fraction of drugs depends on various different factors like total drug concentration, affinity to proteins, protein concentration, presence of endo and exogenic substances (Lakin *et al.*, 1997; Babalola *et al.*, 2004; Welch *et al.*, 1975).

Obtained results showed that antipyrine and caffeine were bonded by plasma proteins at a very low level and paracetamol at a moderate level. Slightly higher values according to antipyrine (3.3-4.8%) and caffeine (3.5-5.2%) were observed in humans (Posti, 1999; Linday *et al.*, 1991; Welch *et al.*, 1975).

CONCLUSION

In this study, the results obtained in the experiment (not statistically significant differences in pharmacokinetic parameter values of antipyrine and caffeine and statistically significant according to paracetamol) determined on the basis of model drugs concentration in blood and saliva showed that saliva has potential to be used as a biological material from calves but only for evaluation of pharmacokinetics of antipyrine and caffeine. However, it cannot be used for assessment of pharmacokinetics of paracetamol.

REFERENCES

- Adzu, B., M. Garba, A. Haruna, M. Maman, C. Wambebe and K. Gamaniel, 2001. Effect of nprisan on single oral dose pharmacokinetics of paracetamol in rats. *Eur. J. Drug Metab. Pharmacokinet.*, 26: 201-204.
- Ali, B.H., Z. Cheng, G. El Hadrami, A.K. Bashir and Q.A. McKellar, 1996. Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. *J. Vet. Pharmacol. Ther.*, 19: 238-244.
- Allegaert, K., B.J. Anderson, G. Naulaers, J. Hoon and R. Verbesselt *et al.*, 2004a. Intravenous paracetamol (Propacetamol) pharmacokinetics in term and preterm neonates. *Eur. J. Clin. Pharmacol.*, 60: 191-197.
- Allegaert, K., C.D. van der Marel, A. Debeer, M Plum and R.A. van Lingen *et al.*, 2004b. Pharmacokinetics of single dose intravenous propacetamol in neonates: Effect of gestational age. *Arch. Dis. Childhood*, 89: F25-F28.
- Aramaki, S., E. Suzuki, O. Ishidaka, A. Momose and K. Umemura, 1991. Pharmacokinetics of caffeine and its metabolites in horses after intravenous, intramuscular or oral administration. *Chem. Pharm. Bull.*, 39: 2999-3002.
- Babalola, C.P., F.A. Oladimeji and M.N. Femi-Oyewo, 2004. Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians. *West Afr. J. Med.*, 23: 10-14.
- Bannwarth, B. and F. Pehourcq, 2003. Pharmacologic basis for using paracetamol: Pharmacokinetic and pharmacodynamic issues. *Drugs*, 63: 5-13.
- Bock, K.W., J. Wiltfang, R. Blume, D. Ullrich and J. Bircher, 1987. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. *Eur. J. Clin. Pharmacol.*, 31: 677-683.
- Boothe, D.M., J.M. Cullen, J.A. Calvin, W.L. Jenkins, S.A. Brown, R.A. Green and D.E. Corrier, 1994. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease. *Am. J. Vet. Res.*, 55: 254-261.
- Danielson, T.J. and L.R. Golsteyn, 1996. Systemic clearance and demethylation of caffeine in sheep and cattle. *Drug Metab. Dispos.*, 24: 1058-1061.
- De Graves, F.J., D.C. Ruffin, S.H. Duran, J.S. Spano, E.M. Whatley, J. Schumacher and M.G. Riddell, 1995. Pharmacokinetics of caffeine in lactating dairy cows. *Am. J. Vet. Res.*, 56: 619-622.
- De Wildt, S.N., G.L. Kearns, J.S. Leeder and J.N. van den Anker, 1999. Glucuronidation in humans. Pharmacogenetic and developmental aspects. *Clin. Pharmacokinet*, 36: 439-452.
- Depelchin, B.O., S. Bloden, C. Michaux and M. Ansay, 1988. Effect of age, sex and breed on antipyrine disposition in calves. *Res. Vet. Sci.*, 44: 135-138.
- Engelking, L.R., G.T. Blyden, J. Lofstedt and D.J. Greenblatt, 1987. Pharmacokinetics of antipyrine, acetaminophen and lidocaine in fed and fasted horses. *J. Vet. Pharmacol. Ther.*, 10: 73-82.

- Flouvat, B., A. Leneveu, S. Fitoussi, B. Delhotal-Landes and A. Gendron, 2004. Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects. *Int. J. Clin. Pharmacol. Ther.*, 42: 50-57.
- Hahn, T.W., S.W. Henneberg, R.J. Holm-Knudsen, K. Eriksen, S.N. Rasmussen and M. Rasmussen, 2000. Pharmacokinetic of rectal paracetamol after repeated dosing in children. *Br. J. Anaesth.*, 85: 512-519.
- Higaki, K., M. Ishii, H. Esumi, M. Kanayama, K.I. Ogawara and T. Kimura, 2003. Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. *Xenobiotica*, 33: 1097-1108.
- Janus, K. and B. Grochowina, 2006a. Effects of age on the pharmacokinetics of paracetamol in calves (In Polish). *Medycyna Wet.*, 62: 193-196.
- Janus, K. and B. Grochowina, 2006b. Trials to evaluate the biotransformation activity of the liver in calves using a simplified paracetamol test (In Polish). *Medycyna Wet.*, 62: 1084-1086.
- Janus, K. and J. Suszycka, 1996. Effect of age on the pharmacokinetics of antipyrine in calves. *Res. Vet. Sci.*, 60: 234-237.
- Janus, K., A. Bartos, M. Kozłowska, S. Suszycki, J. Antoszek and M. Muszczynski, 2007. Pharmacokinetics of caffeine in Black-and-White breed and BW x HF cross-breed calves (In Polish). *Medycyna Wet.*, 63: 696-699.
- Janus, K., B. Grochowina, J. Antoszek, S. Suszycki and Z. Muszczynski, 2003. The effect of food or water deprivation on paracetamol pharmacokinetics in calves. *J. Vet. Pharmacol. Ther.*, 6: 291-296.
- Kawalek, J.C. and K.R. El-Said, 1990. Maturational development of drug-metabolizing enzymes in sheep. *Am. J. Vet. Res.*, 51: 1736-1741.
- Kearns, G.L. and M.D. Reed, 1989. Clinical pharmacokinetics in infants and children. A reappraisal. *Clin. Pharmacokinet.*, 17: 29-52.
- Kennedy, J.M., N.M. Tyers and A.K. Davey, 2003. The influence of morphine on the absorption of paracetamol from various formulations in subjects in the supine position, as assessed by TDx measurement of salivary paracetamol concentrations. *J. Pharm. Pharmacol.*, 55: 1345-1350.
- Lakin, K.M., E.W. Zorian, M.M. Kac, G.M. Aleksandrowa and G.N. Efremowa, 1997. Determination of narcotic substances in saliva in clinical and experimental study (In Russian). *Farmakol. Toksikol.*, 50: 93-97.
- Li, X.D., S.Q. Xia, Y. Lv, P. He, J. Han and M.C. Wu, 2004. Conjugation metabolism of acetaminophen and bilirubin in extrahepatic tissues of rats. *Life Sci.*, 74: 1307-1315.
- Linday, L.A., D.J. Greenblatt, M.P. Warren, J.S. Harmatz, R. De Cresce, C. Cicalese and B.W. Le Duc, 1991. Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. *Dev. Pharmacol. Ther.*, 16: 194-200.
- Mansor, S.M., G. Edwards, P.J. Roberts and S.A. Ward, 1991. The effect of malaria infection on paracetamol disposition in the rat. *Biochem. Pharmacol.*, 41: 1707-1711.
- McNamara, P.J., D. Burgio and S.D. Yoo, 1991. Pharmacokinetics of acetaminophen, antipyrine and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. *Toxicol. Applied Pharmacol.*, 109: 149-160.
- Meffin, P.J., R.L. Williams, T.F. Blaschke and M. Rowland, 1977. Application of salivary concentration data to pharmacokinetic studies with antipyrine. *J. Pharm. Sci.*, 66: 135-137.
- Miller, R.P., R.J. Roberts and L.J. Fischer, 1976. Acetaminophen elimination kinetics in neonates, children and adults. *Clin. Pharmacol. Ther.*, 19: 284-294.
- Miners, J.O., K.J. Lillywhite, K. Yoovathaworn, M. Pongmarutai and D.J. Birkett, 1990. Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. *Biochem. Pharmacol.*, 40: 595-600.
- Monshouwer, M., R.F. Witkamp, A. Pijpers, J.H. Verheijden and A.S. van Miert, 1994. Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol *in vivo* and *in vitro* when administered as a cocktail in pig. *Xenobiotica*, 24: 347-355.
- Monshouwer, M., R.F. Witkamp, S.M. Nijmeijer, A. Pijpers, J.H. Verheijden and A.S. van Miert, 1995. Selective effects of a bacterial infection (*Actinobacillus pleuropneumoniae*) on the hepatic clearances of caffeine, antipyrine, paracetamol and indocyanine green in the pig. *Xenobiotica*, 25: 491-499.
- Peck, K., K.L. Mealey, N.S. Matthews and T.S. Taylor, 1997. Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys. *Am. J. Vet. Res.*, 58: 881-884.
- Posti, J., 1999. Drug concentration in plasma and saliva-physiological and pharmacokinetic examination. *Pharm. Acta Helv.*, 54: 191-199.

- Wasfi, I.A., N.S. Boni, M. Elghazali, A.A. Abdel Hadi, A.M. Almuhrami, I.M. Barezaig and N.A. Alkatheeri, 2000. The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. *Res. Vet. Sci.*, 69: 69-74.
- Welch, R.M., R.L. De Angelis, M. Wingfield and T.W. Farmer, 1975. Elimination of antipyrine from saliva as a measure of metabolism in man. *Clin. Pharmacol. Ther.*, 18: 249-258.
- Wynne, H.A., L.H. Cope, B. Herd, M.D. Rawlins, O.F. James and K.W. Woodhouse, 1990. The association of age and frailty with paracetamol conjugation in man. *Age Ageing*, 19: 419-424.
- Zylber-Katz, E., L. Granit and M. Levy, 1984. Relationship between caffeine concentrations in plasma and saliva. *Clin. Pharmacol. Ther.*, 36: 133-137.